Drug profile · INN
isopropamide iodide
DARBID
isopropamide iodide (DARBID) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — isopropamide iodide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
isopropamide iodide (DARBID) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M1 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is isopropamide iodide?
isopropamide iodide (DARBID) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for isopropamide iodide?
DARBID is a marketed brand name for isopropamide iodide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of isopropamide iodide?
isopropamide iodide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.